CN1775784A - Ceftazidime pentahydrate purifying method - Google Patents
Ceftazidime pentahydrate purifying method Download PDFInfo
- Publication number
- CN1775784A CN1775784A CN 200410090879 CN200410090879A CN1775784A CN 1775784 A CN1775784 A CN 1775784A CN 200410090879 CN200410090879 CN 200410090879 CN 200410090879 A CN200410090879 A CN 200410090879A CN 1775784 A CN1775784 A CN 1775784A
- Authority
- CN
- China
- Prior art keywords
- ceftazime
- ceftazidime
- acid
- aqueous solution
- purification process
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
The method relates to a method for purifying ceftazidime, more concretely relating to a method for preparing high quality ceftazidime pentahydrate by impure, high-polymer impurity content ceftazidime through crystallization. It prepares impure, high-polymer impurity content ceftazidime pentahydrate, ceftazidime Hcl, ceftazidime hydrobromide or ceftazidime overdue or recovered from the market, into a ceftazidime water solution, then regulates the pH value of the ceftazidime water solution to 1.5-2.5 by alkali or acid, here the impurity ceftazidime polymer is separated out with a little ceftazidime, and the separated-out matter is filtered, and the pH value of the filtrate is regulated to 3.5-4.8 by alkali so that the ceftazidime pentahydrate crystals are separated out. The method is simple and convenient to operate, low-cost, good-safety and high-yield. The obtained ceftazidime pentahydrate crystals are high purity and the polymer is low-content, reaching pharmacopoeia specified requirements.
Description
Technical field
The present invention relates to the purification process of ceftazime, more particularly, relate to the method for preparing high-quality ceftazidime pentahydrate by ceftazime impure, that contain polymeric impurities by crystallization.
Background technology
Ceftazidime pentahydrate is to use utmost point cynnematin widely clinically, and its structural formula is as follows:
In order to ensure the human body drug safety, the state-promulgated pharmacopoeia regulation for the ceftazime microbiotic, requires the content of ceftazidime pentahydrate to be not less than 95%, and the content of polymkeric substance is not higher than 0.3%, and its color and luster is not higher than look No. 6.The ceftazime microbiotic is in depositing process, particularly suffer under the situation of high temperature (＞50 ℃), degraded and polyreaction often take place, generate ceftazime dipolymer, trimer and polymer or the like polymkeric substance, thereby cause active constituents of medicine content to reduce, color and luster is strengthened, and polymeric impurities content raises.In addition, out of date ceftazime microbiotic because the shelf-time is long, also usually is that active constituents of medicine content reduces, and darkens, and polymer content raises.Also have, in some cases, because controlling of production process is improper, resulting ceftazidime pentahydrate, ceftazime dipolymer, trimer and polymer or the like polymer content is high especially.And polymer content easily makes human body produce anaphylaxis when high.So for this base polymer foreign matter content high ceftazidime pentahydrate or ceftazime pharmaceutical preparation, be necessary further to carry out purifying, obtain ceftazidime pentahydrate crystal high-quality, that purity is high.
GB2063871 has disclosed ceftazidime pentahydrate crystalline preparation method, and this method is that the pH of the adjusting ceftazime hydrochlorate or the alkali salt aqueous solution is 3.3～4.0, and the ceftazidime pentahydrate crystal structure is separated out.Ceftazidime pentahydrate that above-mentioned polymeric impurities content is higher or ceftazime pharmaceutical preparation, for example, polymeric impurities content is higher than at 4% o'clock, method crystallization purifying according to GB2063871, polymeric impurities often is accompanied by the ceftazidime pentahydrate crystal and separates out together, so the content of polymeric impurities is still very high in the resulting ceftazidime pentahydrate crystal.
GB2157682 discloses a kind of recovery method of ceftazime, this method is to adopt the NOT-function large hole mesh resin, is that 2.0～5.5 ceftazime aqueous solution contact with pH, thereby absorbs ceftazime, carry out wash-out again, isolate ceftazime or its salt or its hydrate.According to the method, final product may be ceftazime or its salt or its hydrate, and the impurity polymer content reduces, product color shoals, but this method need be used the NOT-function large hole mesh resin, carries out wash-out, separation again, operation is many, complex operation, cost height.
US4659813 discloses a kind of ceftazidime pentahydrate crystalline preparation method, this method is, under about 5～15 ℃ temperature, pH is about ceftazime aqueous solution of 5.5～about 6.5, regulating its pH with acid is about 4.0～about 4.7, and in crystallisation process by the adding of control acid, make pH be maintained at about 4.0～about 4.7, thereby separate out the ceftazidime pentahydrate crystal.Though this method is to improving product purity, reducing polymer content has certain help, and the ceftazime preparation very high for polymer content, that color and luster is very poor in this way, still can not get high-quality ceftazidime pentahydrate crystal.Simultaneously, this method is dissolved in material in the higher system of pH earlier, causes ceftazime to be degraded to some extent, and the rate of recovery reduces like this.
Summary of the invention
Therefore, the objective of the invention is to, at the high ceftazime of impurity polymer content provide a kind of easy, can effectively remove the ceftazime purification process of polymeric impurities, also promptly prepare high-quality ceftazidime pentahydrate crystalline method.
The invention provides a kind of purification process that contains the ceftazime of polymeric impurities, this method comprises:
The ceftazime that will contain polymeric impurities adds in the entry, randomly adds acid and makes its dissolving, obtains the ceftazime aqueous solution; PH with the alkali or the acid adjusting ceftazime aqueous solution is 1.5～2.5 then, has precipitation to separate out; Remove by filter precipitation, it is 3.5～4.8 that resulting filtrate continues to regulate pH with alkali, and controlled temperature is at 0～40 ℃, and the ceftazidime pentahydrate crystal structure is separated out.
Ceftazidime pentahydrate impure, that polymer content is high, ceftazime hydrochloride or ceftazime hydrobromate and ceftazime preparation out of date or from retrieving on the market, all can adopt method of the present invention, make with extra care, obtain pure ceftazidime pentahydrate.For ceftazidime pentahydrate impure, that contain polymkeric substance, it is scattered in the water, add acid and make its dissolving, obtain the ceftazime aqueous solution; Ceftazime hydrochloride impure, that contain polymkeric substance or ceftazime hydrobromate can be directly soluble in water, obtain the ceftazime aqueous solution; Ceftazime preparation impure, that contain polymkeric substance, for example ceftazime contains yellow soda ash or ceftazime contains arginine, can be directly soluble in water, obtain the ceftazime aqueous solution.In the method for the invention, the ceftazime aqueous solution that obtains like this, ceftazime content is generally 5wt.%～60wt.%, preferred 10wt.%～40wt.%.
Described polymeric impurities is a ceftazime in preparation and ceftazime dipolymer, trimer and polymer of depositing in the process to be generated or the like mixture of polymers, when the content of these polymeric impurities in ceftazime is higher than 1wt.%, be particularly suited for adopting method of the present invention to carry out purifying.
The acid that is used for the inventive method can be mineral acid or organic acid, and wherein said mineral acid comprises hydrochloric acid, phosphoric acid or sulfuric acid, preferred hydrochloric acid; Described organic acid comprises formic acid or acetate.The adding mode of described acid, the preferred mode that under agitation drips that adopts.
The alkali that is used for the inventive method comprises mineral alkali or organic bases, and wherein said mineral alkali comprises sodium hydroxide solution, potassium hydroxide solution, sodium acetate, Sodium isooctanoate or ammoniacal liquor etc.; Described organic bases comprises triethylamine or n-Butyl Amine 99 etc.The adding mode of described alkali, the preferred mode that under agitation drips that adopts.
In purification process provided by the invention, when preparing the ceftazime aqueous solution, under 0～30 ℃ of temperature, carry out usually by the ceftazime that contains polymeric impurities.PH with the alkali or the acid adjusting ceftazime aqueous solution is 1.5～2.5 then, this moment, polymeric impurities was all separated out basically, be attended by a spot of ceftazime (be about in the solution ceftazime total amount 0.5%～2%) simultaneously and separate out together, by filtering, thereby removed polymeric impurities.Filtering the resulting filtrate in back, to regulate pH with alkali be 3.5～4.8, preferred 4.0～4.6, and this moment, the ceftazidime pentahydrate crystal began to separate out, and recrystallization temperature is controlled at 0～40 ℃, preferred 5～30 ℃, and under this temperature, stir or left standstill growing the grain 1～10 hour.Then, after filtration, solvent wash, drying, obtain the ceftazidime pentahydrate crystal.
In ceftazime purification process provided by the present invention, in order to obtain coloury ceftazidime pentahydrate crystal, preferably add activated carbon and decolour in purge process, the consumption of activated carbon is 2%～30% (weight) that contains the ceftazime of polymeric impurities.
The invention has the advantages that: method of the present invention is particularly useful for the purifying of the high ceftazidime pentahydrate of polymeric impurities content, amorphous ceftazime, ceftazime salt or ceftazime pharmaceutical preparation, resulting ceftazidime pentahydrate crystal purity height behind the purifying, polymer content is low, for example, be lower than 0.2%, reach the pharmacopeia specified requirement.This method is easy and simple to handle, and cost is low, and security is good, the yield height.
Embodiment
In the present invention, according to " Chinese pharmacopoeia (2000 editions, the 171st page to 172 pages, Chemical Industry Press) Gui Ding measuring method, adopt the content of high effective liquid chromatography for measuring ceftazime, according to the content of column chromatography mensuration ceftazime polymkeric substance, following indication content is all according to " the described dry product of pressing of Chinese pharmacopoeia (2000 editions) calculates.
The embodiment that provides below is used for specifically describing embodiment of the present invention, and these embodiment do not limit the scope of the invention.
Embodiment 1
Underproof ceftazidime pentahydrate is 90.1wt.% by the content of high effective liquid chromatography for measuring ceftazime, is 8.5wt.% by the content of measuring polymkeric substance according to column chromatography.
Above-mentioned underproof ceftazidime pentahydrate 20.0g is suspended in the 100ml water, is cooled to 0～5 ℃ with ice-water bath, it is molten clear to material to drip the 36wt.% concentrated hydrochloric acid while stirring, obtains the ceftazime aqueous solution.Under agitation condition, in the ceftazime aqueous solution, drip the NaOH solution of 2N, transfer pH to 2.5, separate out the precipitation of off-white color, elimination precipitation (precipitation weight in wet base 1.99g, HPLC detects and contains ceftazime 0.25g) obtains filtrate.Then, resulting filtrate is warming up to 5～10 ℃ with ice-water bath again, stirs the NaOH solution that drips 2N down, and making pH is 4.0, and the ceftazidime pentahydrate crystal is separated out, again with ice-water bath with temperature regulation to 0～5 ℃, stirred growing the grain 8 hours.Suction filtration then earlier with 30ml water, use the 50ml washing with acetone then, is drained, and vacuum-drying must ceftazidime pentahydrate 16.0g.Molar yield is 87.9%, content 98.5wt%, polymkeric substance 0.08wt.%, weight loss on drying 14.0wt.%.
Embodiment 2
The underproof ceftazidime pentahydrate 20.0g of embodiment 1 is suspended in the 100ml water, is cooled to 0～5 ℃ with ice-water bath, it is molten clear to material to drip 99wt.% acetate while stirring, obtains the clarifying ceftazime aqueous solution.Then, in the resulting ceftazime aqueous solution, add the 0.5g activated carbon, stir decolouring 30 minutes, then remove by filter activated carbon, obtain filtrate.The continuation of resulting filtrate makes temperature be in 0～5 ℃ with ice-water bath, under agitation condition, drips 22wt.% ammoniacal liquor, transfers pH to 2.0, separates out the precipitation of off-white color, and the elimination precipitation obtains filtrate.Then, resulting filtrate is warming up to 20～25 ℃ with water-bath again, stirs to drip 22wt.% ammoniacal liquor down, and making pH is 4.2, and the ceftazidime pentahydrate crystal is separated out, again with ice-water bath with temperature regulation to 0～5 ℃ static growing the grain 6 hours.Suction filtration then earlier with 30ml water, use the 50ml washing with acetone then, is drained, and vacuum-drying must ceftazidime pentahydrate 15.0g.Molar yield 83.2%, content 98.9wt.%, polymkeric substance 0.07wt.%, weight loss on drying 13.9wt.%.
Embodiment 3
The underproof ceftazidime pentahydrate 20.0g of embodiment 1 is suspended in the 30ml water, is cooled to 0～5 ℃ with ice-water bath, it is molten clear to material to drip 36wt.% hydrochloric acid while stirring, obtains the clarifying ceftazime aqueous solution.Then, in the resulting ceftazime aqueous solution, add the 0.5g activated carbon, stir decolouring 30 minutes, then remove by filter activated carbon, obtain filtrate.The continuation of resulting filtrate makes temperature be in 0～5 ℃ with ice-water bath, under agitation condition, drips 22wt.% ammoniacal liquor, transfers pH to 2.0, separates out the precipitation of off-white color, and the elimination precipitation obtains filtrate.Then, resulting filtrate is warming up to 20～25 ℃ with water-bath again, stirs to drip 22wt.% ammoniacal liquor down, and making pH is 3.8, and the ceftazidime pentahydrate crystal is separated out, again with ice-water bath with temperature regulation to 0～5 ℃ growing the grain 4 hours.Suction filtration then earlier with 30ml water, use the 50ml washing with acetone then, is drained, and vacuum-drying must ceftazidime pentahydrate 15.5g.Molar yield 86.0%, content 98.8wt.%, polymkeric substance 0.08wt.%, weight loss on drying 14.1wt.%.
Embodiment 4
23 ℃ of room temperatures, the underproof ceftazidime pentahydrate 20g of embodiment 1 is suspended in the 160ml water, it is molten clear to material to drip 36wt.% hydrochloric acid while stirring, obtains the clarifying ceftazime aqueous solution.In the resulting ceftazime aqueous solution, add the 1g activated carbon, stir decolouring 15 minutes, then remove by filter activated carbon, obtain filtrate.Resulting filtrate under agitation drips triethylamine, transfers pH to 1.8, separates out the precipitation of off-white color, and the elimination precipitation obtains filtrate.Then, resulting filtrate under agitation drips triethylamine, and making pH is 3.9, and the ceftazidime pentahydrate crystal is separated out, again with ice-water bath with temperature regulation to 0～5 ℃, stirred growing the grain 1 hour.Suction filtration then earlier with 30ml water, use the 50ml washing with acetone then, is drained, and vacuum-drying must ceftazidime pentahydrate 11.2g.Molar yield 61.7%, content 98.5wt.%, polymkeric substance 0.1wt.%, weight loss on drying 14.1wt.%.
Embodiment 5
The underproof ceftazidime pentahydrate 20g of embodiment 1 is suspended in the 40ml water, is cooled to 0～5 ℃ with ice-water bath, it is molten clear to material to drip 36wt.% hydrochloric acid while stirring, obtains the clarifying ceftazime aqueous solution.Then, in the resulting ceftazime aqueous solution, add the 3g activated carbon, stir decolouring 50 minutes, then remove by filter activated carbon, obtain filtrate.Resulting filtrate water is bathed and is made temperature be in 10～15 ℃, under agitation condition, drips the 1.5N sodium acetate, transfers pH to 2.0, separates out the precipitation of off-white color, and the elimination precipitation obtains filtrate.Then, resulting filtrate is used water-bath temperature adjustment to 10～15 ℃ again, stirs to drip the 1.5N sodium acetate down, and making pH is 4.0, and the ceftazidime pentahydrate crystal is separated out, again with ice-water bath with temperature regulation to 0～5 ℃ static growing the grain 3 hours.Suction filtration then earlier with 30ml water, use the 50ml washing with acetone then, is drained, and vacuum-drying must ceftazime five water thing 16.1g.Molar yield 89.1%, content 98.0wt.%, polymkeric substance 0.12wt.%, weight loss on drying 14.2wt.%.
Embodiment 6
Underproof ceftazime hydrochloride is 93.1wt.% by the content of high effective liquid chromatography for measuring ceftazime, is 5.5wt.% by the content of measuring polymkeric substance according to column chromatography.
Above-mentioned underproof ceftazime hydrochloride 20g is added in the 100ml water, be cooled to 0～5 ℃, obtain the ceftazime aqueous solution with ice-water bath.Under agitation condition, in the resulting ceftazime aqueous solution, drip the 8N Sodium isooctanoate, transfer pH to 2.5, separate out the off-white color precipitation, the elimination precipitation obtains filtrate.Then, resulting filtrate is retained to 0～5 ℃ with ice-water bath again, stirs down and drips the 8N Sodium isooctanoate, and making pH is 4.4, and the ceftazidime pentahydrate crystal is separated out, static growing the grain 5 hours.Suction filtration then earlier with 30ml water, use the 50ml washing with acetone then, is drained, and vacuum-drying must ceftazime five water thing 15.0g.Molar yield 80.6%, content 99.2wt.%, polymkeric substance 0.1wt.%, weight loss on drying 14.0wt.%.
Embodiment 7
His preparation of underproof cephalo is 81.5% by the content of high effective liquid chromatography for measuring ceftazime, is 5.5wt.% by the content of measuring polymkeric substance according to column chromatography, yellow soda ash 10wt.% (pressing the 351st page of measuring method of American Pharmacopeia XXIV version).
He preparation 20g adds among the 80ml with above-mentioned underproof cephalo, and dissolving is cooled to 0～5 ℃ with ice-water bath, drips 6N hydrochloric acid while stirring and transfers pH to 1, obtains the ceftazime aqueous solution.Under agitation condition, in the resulting ceftazime aqueous solution, drip 6NNaOH and transfer pH to 2.4, separate out the off-white color precipitation, the elimination precipitation obtains filtrate.Then, resulting filtrate is warming up to 20～25 ℃ with water-bath again, stirs to drip 6NNaOH down and transfer pH to 3.7, and the ceftazidime pentahydrate crystal is separated out gradually, again with ice-water bath with temperature regulation to 0～5 ℃ static growing the grain 5 hours.Suction filtration then earlier with 30ml water, use the 50ml washing with acetone then, is drained, and vacuum-drying must ceftazime five water thing 13.2g.Molar yield 81.0%, content 99.1wt.%, polymkeric substance 0.06wt.%, weight loss on drying 13.9wt.%.
Embodiment 8
The underproof ceftazidime pentahydrate 20g of embodiment 1 is suspended in the 120ml water, and it is molten clear to material to drip 99wt.% acetate while stirring, obtains the clarifying ceftazime aqueous solution.Then, 30～35 ℃ of temperature, under agitation condition, drip 22wt.% ammoniacal liquor in resulting solution, transfer pH to 1.6, separate out the precipitation of off-white color, the elimination precipitation obtains filtrate.Resulting filtrate is stirred and is dripped 22wt.% ammoniacal liquor down, and making pH is 4.7, and the ceftazidime pentahydrate crystal is separated out, again with ice-water bath with temperature regulation to 0～5 ℃ static growing the grain 6 hours.Suction filtration then earlier with 30ml water, use the 50ml washing with acetone then, is drained, and vacuum-drying must ceftazidime pentahydrate 14.2g.Molar yield 78.8%, content 98.4wt.%, polymkeric substance 0.09wt.%, weight loss on drying 13.7wt.%.
Claims (7)
1. purification process that contains the ceftazime of polymeric impurities, this method comprises:
The ceftazime that will contain polymeric impurities adds in the entry, randomly adds acid and makes its dissolving, obtains the ceftazime aqueous solution; PH with the alkali or the acid adjusting ceftazime aqueous solution is 1.5～2.5 then, has precipitation to separate out; Remove by filter precipitation, it is 3.5～4.8 that resulting filtrate continues to regulate pH with alkali, and controlled temperature is at 0～40 ℃, and the ceftazidime pentahydrate crystal structure is separated out.
2. purification process according to claim 1 is characterized in that, described acid is hydrochloric acid, phosphoric acid, sulfuric acid, formic acid or acetate.
3. purification process according to claim 1 is characterized in that, described alkali is sodium hydroxide solution, potassium hydroxide solution, sodium acetate, Sodium isooctanoate, ammoniacal liquor, triethylamine or n-Butyl Amine 99.
4. according to claim 2 or 3 described purification process, it is characterized in that, removing by filter post precipitation, it is 4.0～4.6 that resulting filtrate is regulated pH with alkali.
5. purification process according to claim 4 is characterized in that, described controlled temperature is 5～30 ℃.
6. purification process according to claim 1 is characterized in that, the described ceftazime aqueous solution, and the concentration of ceftazime is 5wt.%～60wt.%.
7. purification process according to claim 6 is characterized in that, the described ceftazime aqueous solution, and the concentration of ceftazime is 10wt.%～40wt.%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB200410090879XA CN1328281C (en) | 2004-11-16 | 2004-11-16 | Ceftazidime pentahydrate purifying method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB200410090879XA CN1328281C (en) | 2004-11-16 | 2004-11-16 | Ceftazidime pentahydrate purifying method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1775784A true CN1775784A (en) | 2006-05-24 |
| CN1328281C CN1328281C (en) | 2007-07-25 |
Family
ID=36765521
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB200410090879XA Active CN1328281C (en) | 2004-11-16 | 2004-11-16 | Ceftazidime pentahydrate purifying method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1328281C (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103044457A (en) * | 2012-10-22 | 2013-04-17 | 深圳华润九新药业有限公司 | Method for purifying ceftazidime |
| CN103467496A (en) * | 2013-09-29 | 2013-12-25 | 广州白云山制药股份有限公司广州白云山化学制药厂 | Preparing method of 7-((thiazolyl hydroxyl imino group) acetamido)-3-methyl cephalosporanic acid and another purpose |
| CN103864819A (en) * | 2014-03-31 | 2014-06-18 | 悦康药业集团有限公司 | Ceftazidime compound and pharmaceutical composition thereof |
| CN109824698A (en) * | 2019-01-23 | 2019-05-31 | 华北制药河北华民药业有限责任公司 | A kind of preparation method of cefotaxime |
| CN110396104A (en) * | 2018-07-26 | 2019-11-01 | 赛法洛抗生素有限公司 | The new indication of Tai Siting cefotaxime pharmaceutical preparation treatment gynecological infection |
| CN110857308A (en) * | 2018-08-24 | 2020-03-03 | 浙江长典医药有限公司 | Preparation method of ceftazidime for injection |
| CN111196818A (en) * | 2018-11-19 | 2020-05-26 | 浙江长典医药有限公司 | Preparation method of ceftazidime for injection |
| CN112345669A (en) * | 2020-11-17 | 2021-02-09 | 海南卫康制药(潜山)有限公司 | Method for measuring ceftazidime polymer for injection |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4329453A (en) * | 1979-10-02 | 1982-05-11 | Glaxo Group Limited | Cephalosporin antibiotic |
| US4659813A (en) * | 1984-11-08 | 1987-04-21 | Eli Lilly And Company | Crystallization process for ceftazidime derivative |
-
2004
- 2004-11-16 CN CNB200410090879XA patent/CN1328281C/en active Active
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103044457A (en) * | 2012-10-22 | 2013-04-17 | 深圳华润九新药业有限公司 | Method for purifying ceftazidime |
| CN103044457B (en) * | 2012-10-22 | 2014-07-02 | 深圳华润九新药业有限公司 | Method for purifying ceftazidime |
| CN103467496A (en) * | 2013-09-29 | 2013-12-25 | 广州白云山制药股份有限公司广州白云山化学制药厂 | Preparing method of 7-((thiazolyl hydroxyl imino group) acetamido)-3-methyl cephalosporanic acid and another purpose |
| CN103864819A (en) * | 2014-03-31 | 2014-06-18 | 悦康药业集团有限公司 | Ceftazidime compound and pharmaceutical composition thereof |
| CN110396104A (en) * | 2018-07-26 | 2019-11-01 | 赛法洛抗生素有限公司 | The new indication of Tai Siting cefotaxime pharmaceutical preparation treatment gynecological infection |
| CN110857308A (en) * | 2018-08-24 | 2020-03-03 | 浙江长典医药有限公司 | Preparation method of ceftazidime for injection |
| CN110857308B (en) * | 2018-08-24 | 2021-02-26 | 浙江长典医药有限公司 | Preparation method of ceftazidime for injection |
| CN111196818A (en) * | 2018-11-19 | 2020-05-26 | 浙江长典医药有限公司 | Preparation method of ceftazidime for injection |
| CN109824698A (en) * | 2019-01-23 | 2019-05-31 | 华北制药河北华民药业有限责任公司 | A kind of preparation method of cefotaxime |
| CN112345669A (en) * | 2020-11-17 | 2021-02-09 | 海南卫康制药(潜山)有限公司 | Method for measuring ceftazidime polymer for injection |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1328281C (en) | 2007-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1775784A (en) | Ceftazidime pentahydrate purifying method | |
| CN109608476B (en) | Method for treating production waste liquid of cephalosporin antibiotics and production method | |
| CN1056650C (en) | Natamycin recovery | |
| US6518456B1 (en) | Process for the production of 1-(aminomethyl)-cyclohexyl-acetic acid in pure form | |
| US7393974B2 (en) | Process for the preparation of 1-(aminomethyl) cyclohexaneacetic acid | |
| CN1209364C (en) | Amine salt of cefathiamiding, its preparing method and application | |
| CN105683170A (en) | Method of refining valsartan comprising more than 10% d-isomers | |
| EP0254486B1 (en) | Preparation of metal gluconates | |
| CN111018731B (en) | Extraction method of tyrosine | |
| CN110627637B (en) | One-step method for preparing racemic ketone isoleucine calcium | |
| CN114149477A (en) | Crystallization method of high-purity vitamin B12 crystal and product thereof | |
| CN1229332C (en) | Extraction process of 15N-L-phenylalanine | |
| CN1432566A (en) | Prepn and purification process of sodium dimercapto propane sulfonate | |
| CN112142740A (en) | Process for the preparation of imipenem | |
| JP3257105B2 (en) | Method for producing zirconium oxychloride crystal | |
| KR100645598B1 (en) | Method for Preparing Sodium Cyanide Having High Purity | |
| CN113429366B (en) | Preparation method of chlorpromazine hydrochloride | |
| US7161029B2 (en) | DiL-lysine monosulfate trihydrate crystal and method of making | |
| CN109535028B (en) | Method for preparing pure anilinoacetonitrile by suspension melting crystallization method | |
| CN104447714A (en) | Production process of paroxetine hydrochloride | |
| CN1422807A (en) | Method for preparing LiPF6 | |
| JP2001031419A (en) | Purification of copper sulfate | |
| CN101289417A (en) | Process for preparing D-3-thioacetyl-2-methylpropionyl-L-proline | |
| EP1069109B1 (en) | Process for production of optically active N-protected-N-methyl-phenylalanine derivative | |
| CN1876628A (en) | Method for preparing levocysteine and dextral cysteine using chemical resolution method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |